Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 12, 2016 12:39 AM ET

Personal Products

Company Overview of Nestlé Health Science S.A.

Company Overview

Nestlé Health Science S.A. engages in the manufacture and distribution of nutritional solutions for consumers, patients, and its partners in healthcare worldwide. It offers diagnostics, devices, and drugs for inborn errors of metabolism, paediatric and acute care, obesity care, healthy ageing, and gastrointestinal and brain health; clinical nutritional solutions for metabolic disorders; diagnostics and pharmaceuticals in gastroenterology and oncology; prescription medical foods for the brain and metabolic disorders; botanical-based nutrients for gastrointestinal disorders; an assessment tool to help healthcare professionals identify cases of cow's milk protein allergy or CMPA in infants; and...

Avenue Reller 14

Vevey,  1800


Founded in 2010

Key Executives for Nestlé Health Science S.A.

Chief Executive Officer and Director
Age: 46
Director and Chief Executive Officer of Nestlé S A
Chief Executive Officer of Accera and President of Accera
Head of Nestlé Institute of Health Sciences and Director
Head of Communications
Compensation as of Fiscal Year 2015.

Nestlé Health Science S.A. Key Developments

Seres Therapeutics Announces Strategic Collaboration with Nestle Health Science

Seres Therapeutics has entered into an agreement with Nestle Health Science for the development and commercialization outside of the United States and Canada for its product candidates in development for Clostridium difficile infection (CDI) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The agreement will support the expansion of Seres' portfolio in markets outside of the United States and Canada and provide substantial financial support for Seres' ongoing research and development. Seres retains full commercial rights to its entire portfolio of product candidates in the United States and Canada, where the company plans to build its own commercial organization. Under the agreement, Seres granted Nestle Health Science commercial rights in global markets outside of the United States and Canada to SER-109 and SER-262 for CDI, and SER-287 and SER-301 for IBD. The U.S. Food and Drug Administration (FDA) has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. In exchange for commercial rights, Nestle Health Science agreed to provide Seres with an upfront payment of $120 million in cash and a series of contingent payments for development and sales milestones and tiered royalties on sales ranging from the high single digits percentages up to the high teens for all products. Nestle Health Science agreed to contribute to certain development efforts, including 33% of expenses for potential global Phase 3 studies for SER-287, SER-301 and SER-262. The full potential value of the up-front payment, milestones and royalties payable by Nestle Health Science is over $1.9 billion, assuming all products receive regulatory approval and are successfully commercialized. Seres expects to receive a total of $30 million in milestone payments in 2016 associated with the planned initiation of a Phase 1b study for SER-262 in primary CDI and the anticipated start of the Phase 3 trial for SER-109 in recurrent CDI. The upfront payment to be received under the agreement is expected to help fund the late-stage development of Seres' lead programs, and drive the continued growth of Seres' pipeline in a variety of conditions where addressing the microbiome could be an effective clinical strategy.

Lipid Therapeutics GmbH Signs Licensing Agreement with Nestlé Health Science S.A

Lipid Therapeutics GmbH has entered into a licensing agreement with Nestle Health Science S.A. for exclusive rights to Lipid Therapeutics' LT-02 compound (phosphatidylcholine), a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis (UC), worldwide excluding Europe and Australia. The terms of the license include an upfront fee, milestones payments and royalties on net sales. Under the agreement Nestle Health is responsible for the continued development and commercialization of LT-02 in its territories, with Phase III clinical trials in the US planned to start in 2016. The trials will primarily assess LT-02 as an add-on therapy in patients with UC not adequately responding to standard doses of 5-aminosalicylic acid, the current standard treatment for the condition.

Nestlé Health Science Introduces Innovative BOOST® Nutritional Drinks in Compact Sizes

Nestlé Health Science has announced the launch of the next generation of nutrition drinks -- 4 fluid (fl) ounce (oz) size BOOST Calorie Smart® 100 Calories Balanced Nutritional Drink and BOOST® Compact Complete Nutritional Drink. Research shows that more than 40% of adults are not meeting the recommended daily intake of many vitamins and minerals through diet alone. Key shortfall nutrients for adults 50 years and older include calcium, magnesium, potassium, choline and vitamins A, D and E. Consuming a nutritional drink, such as the new BOOST® drinks, can help older adults get the nutrition they need every day. For some, getting extra nutrition without consuming extra calories can be a challenge. BOOST Calorie Smart® 100 Calories Drink is a great-tasting solution. This unique 100 calorie 4 fl oz snack size drink contains 10 grams of high-quality protein to help maintain muscle, 25 vitamins and minerals to help meet daily nutritional needs, calcium to support bone health and only 2 grams of sugar. It comes in Rich Chocolate and Very Vanilla flavors for a delicious and nutritious snack that can fit into a busy life. New BOOST® Compact Drink is a ground-breaking solution that provides complete nutrition in half the volume of a full size nutritional drink (4 fl oz vs. 8 fl oz in BOOST® Original Drink). Distinct from any product currently on the market, each 4 fl oz bottle is packed with 240 calories, 10 grams of high-quality protein to help maintain muscle and 26 vitamins and minerals to help meet daily nutritional needs. Available in Rich Chocolate and Very Vanilla flavors, it also contains both calcium and vitamin D to support bone health. Nutrient-dense, smaller sized nutritional drinks can help people in need of extra nutrition get the nutrition they need. Studies have shown that older adults who consume a 4 fl oz nutrient-dense nutritional supplement rather than a standard-size nutritional supplement increase their calorie and protein intake significantly.

Similar Private Companies By Industry

Company Name Region
Sunstar Suisse S.A. Europe
L.RAPHAEL Switzerland GmbH Europe
LockStyler SA Europe
FING'RS (Europe) AG Europe
Doetsch Grether AG Europe

Recent Private Companies Transactions

June 30, 2015
Nestlé Health Science S.A., Compat Line of Pumps & Administration Sets in U.S. and Canada

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nestlé Health Science S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at